Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers

Bibliography

• NICHOLLS PJ: Breast cancer management: science andcare together. Pharm. J. (1997) 259:459–470.
   Google Scholar
• SAUNDERS CM, BAUM M: Management of early breastcancer. Oncol. in Pract. (1994) 3:4–8.
   Google Scholar
• BASSETT LW, MANJIKIAN V, GOLD RH: Mammographyand breast cancer screening. Surg. Clin. N Am. (1990) 70:775–800.
   PubMedGoogle Scholar
• LERNER LJ, JORDAN CV: Development ofanti-oestrogens and their use in breast cancer: memorial award lecture. Cancer Res. (1990) 50:4177–4189.
   PubMed Web of Science ®Google Scholar
• KATZENELLENBOGEN BS, MONTANO MM, EKENA K etal.: Antioestrogens: mechanism of action and resistance in breast cancer. Breast Cancer Res. Treat. (1997) 44:23–38.
   PubMed Web of Science ®Google Scholar
• CUENCA RE, GIACHINO J, ARREDONDO MA et al:Endometrial carcinoma associated with breast cancer: low incidence with tamoxifen use. Cancer (1996) 77:2058–2063.
   PubMedGoogle Scholar
• HOWELL A, DOWNEY S, ANDERSON E: New endocrinetherapies for breast cancer. Eur. J. Cancer (1996) 32A:576–588.
   PubMed Web of Science ®Google Scholar
• KRAUS WL, WEIS KE, KATZENELLENBOGEN BS: Inhibi-tory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity in agonist-and antagonist-occupied progestin receptors. Mol. Biol. (1995) 15:1847–1857.
   Google Scholar
• BANTING L: Inhibition ofP450ARome. In: Progress in Medicinal Chemistry. Ellis GP, Luscombe DK (Eds.), Elsevier Science, Amsterdam (1996) 33:147–184.
   Google Scholar
• ••Good review.
   Google Scholar
• LOMBARDI P: The irreversible inhibition of aromatase (oestrogen synthetase) by steroidal compounds. Curr. Pharm. Des. (1995) 1:23–50.
   Google Scholar
• ••Good review.
   Google Scholar
• BANTING L, NICHOLLS PJ, SHAW MA, SMITH HJ: Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer. In: Progress in Medicinal Chemistry. Ellis GP, West GB (Eds.), Elsevier, Amsterdam (1989) 26:253–298.
   PubMedGoogle Scholar
• ••Good review.
   Google Scholar
• ZHOU D, CAM LL, LAUGHTON CA et al.: Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochr ome-P450. j Biol. Chem. (1994) 269:19501–19508.
   PubMed Web of Science ®Google Scholar
• ZHOU D, KORZEKWA KR, POULOS T, CHEN S: A site-directed mutagenesis study of human placental aromatase. j Biol. Chem. (1992) 267:762–768
   PubMedGoogle Scholar
• BANTING L, SMITH HJ, JAMES M et al.: Structure-activityrelationships for non-steroidal inhibitors of aromatase. I Enzym. Inhib. (1988) 2:215–229.
   PubMedGoogle Scholar
• BRODIE AMH: Aromatase inhibitors and breast cancer. In: Hormones and Cancer. Vedeckis WV (Ed.), Birkhauser, Boston, USA (1996).
   Google Scholar
• SHAW MA, NICHOLLS PJ, SMITH HJ: Arninoglutethimide and ketoconazole: historical perspectives and future prospects. j Steroid Biochem. (1988) 31:137–146.
   PubMedGoogle Scholar
• BRODIE AM, SCHWARZEL WC, SHAIKH AA, BRODIE HJ: The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17 -dione, on estrogen-dependent processes in reproduction and breast cancer. Endocri-nology (1977) 100: 1684-1695.
   Google Scholar
• STEELE RE, MELLOR RB, SAWYER WK: In vitro and in vivo studies demonstrating potent and selective oestrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids (1987) 50:147–161.
   PubMedGoogle Scholar
• BHATNAGER AS, HAUSLER A, SCHIEWECK K: Inhibition of aromatase in vitro and in vivo by aromatase inhibi-tors. J. Enzym. Inhib. (1990) 4:179–186.
   PubMedGoogle Scholar
• SMITH IE: Aromatase inhibitors: a dose-response effect? Endocr. Rel. Cancer (1999) 6:245–249.
   PubMedGoogle Scholar
• BHATNAGER AS, HAUSLER A, SCHIEWICK K, LANG M,BOWMAN R: Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. (1990) 37:1021–1027.
   PubMedGoogle Scholar
• PLOURDE PV, DYROFF M, DUKES M: Arimidex: a potentand selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat. (1994) 30:103–111.
   PubMed Web of Science ®Google Scholar
• WALL EVD, DONKER TH, FRANKRIJKER ED, NORTIER HWR, THIJSSEN JHH, BLANKENSTEIN MA: Inhibition of the in vivo conversion of androstenedione to oestrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res. (1993) 53:4563–4566.
   PubMedGoogle Scholar
• EVANS TRJ, DISALLE E, ORNTI G et al.: Phase 1 andendocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. (1992) 52:5933–5939.
   PubMedGoogle Scholar
• EDWARDS PN: From programme sanction to clinicaltrials: a partial view of the quest for ArimidexiM, a potent selective inhibitor of aromatase. In: Introduction to the Principles of Drug Design and Action. Smith HJ (Ed.), Harwood Academic Publishers, Amsterdam (1998) 3:208–235.
   Google Scholar
• •Describes problems associated with getting a drug to market.
   Google Scholar
• LUSCOMBE DK, TUCKER M, PEPPER CJ et al.: Enzyme inhibitors as drugs: from design to the clinic. In: Design of Enzyme Inhibitors as Drugs. Sandler M, Smith HJ (Eds.), OUP, Oxford (1988) 2:1–41.
   Google Scholar
• •Describes metabolic problems of drug development.
   Google Scholar
• KHODARAHMI GA, SMITH HJ, NICHOLLS PJ, AHMADI M:Enantioselectivity of some 1 -[(benzofuran-2 -yl)phenylmethyl] imidazoles as aromatase (P450ARom) inhibitors. J. Pharm. Pharmacol (2000):In press.
   Google Scholar
• DOWSETT M: Drug and hormone interactions ofaromatase inhibitors. Endocr. Ref Cancer (1999) 6:181–185.
   PubMed Web of Science ®Google Scholar
• HAMILTON A, PICCART M: The third-generationnon-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Anna]. Oncol. (1999) 10:377–384.)
   PubMed Web of Science ®Google Scholar
• NUMAZAWA M, YAMAGUCHI S: Synthesis and structure-activity relationships of 6-phenylaliphatic-substituted C-19 steroids having a 1,4-diene, 4,6-diene or 1,4,6-triene structure as aromatase inhibitors. Steroids (1999) 64:187–196.
   PubMed Web of Science ®Google Scholar
• LEBORGNE M, MARCHAND P, DELEVOYESEILLER B, ROBERT JM, LEBAUT G: New selective nonsteroidal aromatase inhibitors. Synthesis and inhibitory activity of 2,3 or 5 -(alphaazoylbenzy1)-1 H-in doles. Bioorg. Med. Chem. Lett. (1999) 9:333–336.
   Google Scholar
• SONNET P, GUILLON J, ENGUEHARD C et al.: Design andsynthesis of a new type of nonsteroidal human aromatase inhibitor. Biorg. Med. Chem. Lett. (1998) 8:1041–1044.
   PubMed Web of Science ®Google Scholar
• MASAMURA S, SANTNER SJ, HEITJAN DF et al.: Estrogendeprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol Metab. (1995) 80:2918–2925.
   PubMed Web of Science ®Google Scholar
• LONNING PE: Cross-resistance to different aromataseinhibitors in breast cancer treatment. Endocr. Rel. Cancer (1999) 6:251–257.
   PubMed Web of Science ®Google Scholar
• CHEN S, ZHOU D, OKUBU T et al.: Breast tumour aromatase: functional role and transcriptional regula-tion. Endocr. Ref Cancer (1999) 6:149–156.
   PubMed Web of Science ®Google Scholar
• SINGH A, PUROHIT A, GHILCHIK MW eta].: The regula-tion of aromatase activity in breast fibroblasts: the role of interleukin -6 and prostaglandin E2. Endocr. Rel. Cancer (1999) 6:139–147.
   Google Scholar
• HARRIS RE, NAMBOODIRI KK, FARRAR WB: Nonsteroidalanti-inflammatory drugs and breast cancer. Epidemi-ology (1996) 7:203–205.
   PubMed Web of Science ®Google Scholar
• PASQUALINI JR, CHETRITE G, BLACKER C et al.: Concen-trations of estrone, estradiol and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J. Endocrinol. Metab. (1996) 81 :1460–1464 .
   PubMed Web of Science ®Google Scholar
• PASQUALINI JR, GELLY C, NGUYEN BL, VELLA C:Importance of estrogen sulfates in breast cancer. J Steroid. Biochem. (1989) 34:155–163.
   PubMedGoogle Scholar
• •A comprehensive account.
   Google Scholar
• POULIN R, LABRIE F: Stimulation of cell proliferationand estrogenic response by adrenal C19-delta-5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res. (1986) 46:4933–4937.
   PubMed Web of Science ®Google Scholar
• FOULKES R, SHAW S, SUITTERS A: Immunologicalconsequences of inhibiting dehydroepiandrosterone sulfatase in vivo. In: Steroid Hormones and the T-cell Cytokine Profile. (Rook GAW, Lightman S (Eds.), Springer, Berlin, Germany (1997):135–152.
   Google Scholar
• RHODES ME, LI PK, BURKE AM, JOHNSON DA: Enhancedplasma DI-1EAS, brain acetylcholine and memory mediated by steroid sulfatase inhibition. Brain Res. (1997) 773:28–32.
   PubMed Web of Science ®Google Scholar
• PARENTI G, MERONI G, BALLABIO A: The sulfatase genefamily. Curr. Opin. Gen. Develop. (1997) 7:386–391.
   PubMed Web of Science ®Google Scholar
• POIRIER D, CIOBANU LC, MALTAIS R: Steroid sulfatase inhibitors. Exp. Opin. Ther. Patents (1999) 9:1083–1099.
   Web of Science ®Google Scholar
• •Good review.
   Google Scholar
• DIBBELT L, KUSS E: Human placental steryl sulfatase: enzyme purification, production of antisera and immunoblotting reactions with normal and sulfatase-deficient patients. Biol. Chem. Hoppe-Seyler (1986) 367:1223–1229.
   PubMedGoogle Scholar
• SCHMIDT B, SELMER T, INGENDOH A et al.: A novel amino acid modification in sulphatases that is defective in multiple sulphatase deficiency. Cell (1995) 82:271–278.
   PubMed Web of Science ®Google Scholar
• BOND CS, CLEMENTS PR, ASHBY SJ et al.: Structure of the lysosomal sulfatase. Structure (1997) 5:277–289.
   PubMed Web of Science ®Google Scholar
• LUKATELA G, KRAUSS N, THEIS K et al.: Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. Biochemistry (1998) 37:3654–3664.
   PubMed Web of Science ®Google Scholar
• WOO LWL, PUROHIT A, MALINI B, REED MJ, POTTER BVL: Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. (2000) 7:773–791.
   PubMedGoogle Scholar
• ••Review of mechanism of action of sulfatase.
   Google Scholar
• EVANS TRJ, ROWLANDS MG, JARMAN M, COOMBES RC:Inhibition of estrone sulfatase in human placenta and human breast carcinoma. J. Steroid. Biochem. Mol. Biol. (1991) 34:493–499.
   Google Scholar
• NGUYEN BL, FERME I, CHETRITE G, PASQUALINI JR:Action of danazol on the conversion of estrone sulphate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells./ Steroid Biochem. Mol. Biol. (1993) 46:17-23.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(5)
   Google Scholar
• HOWARTH NM, PUROHIT A, REED MJ, POTTER BVL: Estr one sulfamates: potent inhibition of estrone sulfatase with therapeutic potential. J Med. Chem. (1994) 37:219–221.
   PubMed Web of Science ®Google Scholar
• PUROHIT A, VERNON KA, HUMMELINCK AEW et al: Thedevelopment of A-ring modified analogues of oestrone-3-asulfamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mot. Biol. (1998) 64:269–275.
   PubMed Web of Science ®Google Scholar
• WOO LWL, HOWARTH NM, PUROHIT etal.: Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med. Chem. (1998) 41:1068–1083.
   Google Scholar
• LI PK, CHU GH, GUO JP, PETERS A, SELCER KW: Develop-ment of potent non-estrogenic estrone sulfatase inhibitors. Steroids (1998) 63:425–432.
   PubMed Web of Science ®Google Scholar
• POIRIER D, BOIVIN representative: 17 a-Alkyl- or 17a-substituted benzy1-1713-estradiols: a new family of oestrone sulphatase inhibitors. Bioorg. Med. Chem. Lett. (1998) 8:1891–1896.
   PubMed Web of Science ®Google Scholar
• CIOBANU LC, BOIVIN KP, LUU-THE V, LABRIE F, POIRIER D: Potent inhibition of steroidal sulfatase activity by 3-0-sulfamate 17 a-benzyl (or 4r-teributylbenzyl) estra-1,3,5(10)-trienes: combination of two substitu-ents at positions C3 and 17a of estradiol. j Med. Chem. (1999) 42:2280–2286.
   PubMed Web of Science ®Google Scholar
• LI PK, MILANO S, KLUTH L, RHODES ME: Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mot. Biol. (1996) 59:41–48.
   PubMed Web of Science ®Google Scholar
• SELCER KW, HEGDE PV, LI PK: Inhibition of estrone sulfatase and proliferation of human breast cancer cells by non-steroidal (p-O-sulfamoy1)-N-alkanoyl tyramines. Cancer Res. (1997) 57:702–707.
   PubMed Web of Science ®Google Scholar
• WOO LWL, PUROHIT A, REED MJ, POTTER BVL: Active site directed inhibition of estrone sulfatase by nonster-oidal coumarin sulfamates. J Med. Chem. (1996) 39:1349–1351.
   PubMedGoogle Scholar
• PUROHIT A, WOO LWL, SINGH A et al.: In vivo activity of 4-methylcoumarin-7-0-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. Cancer Res. (1996) 56:4950–4955.
   PubMedGoogle Scholar
• PUROHIT A, WOO LWL, POTTER BVL, REED MJ: In vivo inhibition of estrone sulfatase and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE Cancer Res. (2000) 60:3394–3396.
   Google Scholar
• RAGAZ J: Status of aromatase inhibitors in relation to other breast cancer treatment modalities. Endocr. Rel. Cancer (1999) 6:277–291.
   PubMed Web of Science ®Google Scholar
• ••Good review.
   Google Scholar
• LUU-THE V, ZHANG Y, POIRIER D, LABRIE F: Character-istics of human Types 1, 2 and 3 1713-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J. Steroid Biochem. Molec. Biol. (1995) 55:581–587.
   PubMed Web of Science ®Google Scholar
• ANDERSSON S: 1713-Hydroxysteroid dehydrogenase:isozymes and mutations. J. Endocrinol. (1995) 146:197–200.
   PubMedGoogle Scholar
• PELTOKETO H, LUUTHE V, SIMARD J et al.: 17 P-Hy dr o x y-steroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family: nomenclature and main characteristics of the 17 HSD/KSR enzymes. j Mot. Endocrinol. (1999) 23:1–11.
   PubMed Web of Science ®Google Scholar
• PELTOKETO H, ISOMAA V, MAENTAUSTA 0, VIHKO R:Complete amino acid sequence of human placental 1713-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett. (1988) 239:73–77.
   PubMed Web of Science ®Google Scholar
• LUU-THE V, LABRIE C, ZHAO HF et al: Characterisationof cDNAs for human estradiol 173-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5' termini in human placenta. Mot. Endocrinol. (1989) 3:1301–1309.
   Google Scholar
• WU L, EINSTEIN M, GEISSLER WM, CHAN HK, ELLISTONKO, ANDERSSON S: Expression cloning and characteri-sation of human 1713-hydroxysteroid dehydrogenase Type 2, a microsomal enzyme possessing 20a-hydro-xysteroid dehydrogenase activity. J Biol. Chem. (1993) 268:12964–12969.
   PubMed Web of Science ®Google Scholar
• GEISSLER WM, DAVID DL, WU L et al.: Male pseudoher-maphr oditism caused by mutations of testicular 173-hydroxysteroid dehydrogenase 3 Nat. Genet. (1994) 7:34–39.
   PubMedGoogle Scholar
• REED MJ, SINGH A, GHILCHIK MW, COLDHAM NG, PUROHIT A: Regulation of estradiol 1713-hydroxyste-roid dehydrogenase in breast tissue - the role of growth factors. J. Steroid Biochem. Mot. Biol. (1991) 39:791–798.
   PubMed Web of Science ®Google Scholar
• JAMES VH, MCNEILL JM, LAI LC, NEWTON CJ, GHILCHIKMW, REED MJ: Aromatase activity in normal breast and breast tumor tissue: in ViVO and in vitro studies. Steroids (1987) 50:269–279.
   PubMedGoogle Scholar
• VERMEULEN A, DESLYPERE JP, PARIDAENS R, LECLERCQG, ROY F, HEUSON JC: Aromatase,1713-hydroxysteroid dehydrogenase and intratissular sex-hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. j Clin. Oncol. (1986) 22:515–525.
   PubMedGoogle Scholar
• BERANEK PA, FOLKERD EJ, NEWTON CJ, REED MJ, GHILCHIK MW, JAMES VHT: The relationship between 17I3-hydroxysteroid dehydrogenase and breast tumour site and size. Int. J. Cancer (1985) 36:685–687.
   PubMedGoogle Scholar
• JAMES VHT, MACNEIL JM, BERANEK PA, BONNEY RC,REED MJ: The role of tissue steroids in regulating aromatase and estradio11713-hydroxysteroid dehydro-genase activities in breast and endometrial cancer. J Steroid Biochem. Mot. Biol. (1986) 25:787–790.
   Google Scholar
• COLDHAM NG, JAMES VHT: A possible mechanism forincreased breast cell-proliferation by progestins through increased reductive 17I3-hydroxysteroid dehydrogenase activity. Int. J. Cancer (1990) 45:174–178.
   PubMedGoogle Scholar
• NEWTON CJ, BUTTA A, NICHOLLS J, DOWSETT M: Estradiol synthesis from estrone in malignant breast epithelial cells -studies on a high affinity, 80KDa form of estradiol dehydrogenase. j Steroid Biochem. Mol. Biol. (1992) 42:891-900.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(5)
   Google Scholar
• MACNEIL JM, REED MJ, BERANEK PA et al.: A comparisonof the in vivo uptake and metabolism of H-3 estrone and H-3 estradiol by normal breast and breast tumour tissues in postmenopausal women. Int. J Cancer (1986) 38:193–196.
   PubMedGoogle Scholar
• BONNEY RC, REED MJ, JAMES VHT: Inhibition of1 713-hydroxysteroid dehydrogenase activity in human en do m etr ium by adrenal androgens. J. Steroid Biochem. Mol. Biol. (1983) 18:59–64.
   Google Scholar
• CASTAGNETTA LA, GRANATA OM, TAIBI G et al:1 713-Hydroxysteroid oxidoreductase activity in intact cells significantly differs from classical enzymology analysis. J. Endocrinol. (1996) 150: S73–S78.
   Google Scholar
• MIETTINEN M, MUSTONEN M, POUTANEN M et al: 17 P-Hydroxysteroid dehydrogenases in normal mammary epithelial cells and breast tissue. Breast Cancer Res. Treat. (1999) 57:175–182.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, MORIYA T, ARIGA N et al.: 1 7 P-Hydroxyste-roid dehydrogenase Type 1 and Type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br. J. Cancer (2000) 82:518–523.
   PubMedGoogle Scholar
• ADAMS EF, COLDHAM NG, JAMES VHT: Steroidal regula-tion of oestradiol 173-dehydrogenase - activity of the human breast cancer cell-line MCF-7. J. Endocrinol. (1988) 118:149–154.
   PubMedGoogle Scholar
• REED MJ, PUROHIT A, DUNCAN LJ et al: The role ofcytokines and sulfatase inhibitors in regulating estrogen synthesis in breast tumours. J. Steroid Biochem. Mol Biol. (1995) 53:413–420.)
   PubMedGoogle Scholar
• MIETTINEN MM, MUSTONEN MVJ, POUTANEN MH, ISOMAA W, VIHKO RJ: Human 1713-hydroxysteroid Type 1 and Type 2 isoenzymes have opposite activities in cultured cells and characteristic cell and tissue specific expression. Biochem J. (1996) 314:839–845.
   PubMedGoogle Scholar
• POUTANEN M, MONCHARMONT B, VIHKO R:173-Hydro-xysteroid dehydrogenase gene-expression in human breast cells - regulation of expression by a progestin. Cancer Res. (1992) 52:290–294.
   PubMed Web of Science ®Google Scholar
• BLOMQUIST CH, LEUNG BS, BEAUDOIN C, POIRIER D, TREMBLAY Y: Intracellular regulation of 17 P-hydroxy-steroid dehydrogenase Type 1 catalytic activity in A431 cells. J. Endocrinol (1997) 153:453–464.
   PubMedGoogle Scholar
• PENNING TM: 1 713-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design. Endocr. Rel. Cancer (1996) 3:41–56.
   Web of Science ®Google Scholar
• ••Good review.
   Google Scholar
• TREMBLAY MR, AUGER S, POIRIER D: Synthesis of1 6-(bromoalkyl)-estradiols having inhibitor effect on estradiol 17 P-hydroxysteroid dehydrogenase (1 7 I3-HSD Type 1). Bioorg. Med. Chem. (1995) 3:505–523.
   PubMed Web of Science ®Google Scholar
• SANTNER SJ, SANTEN RJ: Inhibition of oestronesulfatase and 1 713-hydroxysteroid dehydrogenase by antioestrogens. J. Steroid Biochem. Mol Biol. (1993) 45:383–390.
   PubMedGoogle Scholar
• POIRIER D, DIONNE P, AUGER S: A 63-(thiaheptana-mide) derivative of oestradiol as inhibitor of 1 713-hydroxysteroid dehydrogenase Type 1. J. Steroid Biochem. Mol. Biol. (1998) 64:83–90.
   PubMed Web of Science ®Google Scholar
• PELLETIER JD, POIRIER D: Synthesis and evaluation ofoestradiol derivatives with 1 60C-(bromoalkylamide), 1 60C-(bromoalkyl) or 160C-(bromoalkynyl) side chain as inhibitor of 1 713-hydroxysteroid dehydrogenase Type 1 without estrogenic activity. Bioorg. Med. Chem. (1996) 4:1617–1628.
   PubMed Web of Science ®Google Scholar
• TREMBLAY MR, POIRIER S: Overview of a rationalapproach to design Type 1 1 713-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation. J Steroid Biochem. Mol. Biol. (1998) 66:179–191.
   PubMed Web of Science ®Google Scholar
• SAM KM, AUGER S, LUU-THE V, POIRIER D: Steroidalspiro-7-lactones that inhibit 1 713-hydroxysteroid dehydrogenase activity in human placental microsomes. J. Med. Chem. (1995) 38:4518–4528.
   PubMedGoogle Scholar
• TREMBLAY MR, LUU-THE V, LEBLANC G et al.: Spironolactone-related inhibitors of Type II 1 713-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities and antiprolif-erative activities. Bioorg. Med. Chem. (1999) 7:1013–1023.
   PubMedGoogle Scholar
• CHETRITE GS, KLOOSTERBOER HJ, PHILIPPE JC et al: Effects of Org 0D14 (LivialR) and its metabolites on 17 P-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. AntiCancer Res. (1999) 19:261–267.
   PubMed Web of Science ®Google Scholar
• RUH MF, ZACHAREWSKI T, CONNOR K, HOWELL J, CHENI, SAFES: Naringenin: a weakly estrogenicbioflavanoid that exhibits antiestrogenic activity. Biochem. Pharmacol. (1995) 50:1485–1493.
   PubMed Web of Science ®Google Scholar
• MARKIEWICZ L, GAREY J, ADLERCREUTZ H, GURPIDE E:In vitro bioassays of non-steroidal phytoestrogens. Steroid Biochem. Mol. Biol. (1993) 45:399–405.
   PubMed Web of Science ®Google Scholar
• MOUSAVI Y, ADLERCREUTZ H: Genistein is an effectivestimulator of sex hormone-binding globulin produc-tion in hepatocarcinoma human liver cancer cells and suppresses proliferation of these cells in culture. Steroids (1993) 5 8:301–304.
   Google Scholar
• LE LAIN R, NICHOLLS PJ, SMITH HJ, MAHARLOUIE FH: Inhibitors of human and rat testes microsomal 1 713-hydroxysteroid dehydrogenase (1 713-HSD) as potential agents for prostatic cancer. J Enzym. Inhib. (2000) In press.
   Google Scholar
• EVANS BAJ, GRIFFITHS K, MORTON MS: Inhibition of 50C-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavanoids. J. Endocrinol. (1995) 1 47 :295–302.
   Google Scholar
• GHOSH D, PLETNER VZ, ZHU D-W et al.: Structure of human oestrogenic 1 713-hydroxysteroid dehydroge-nase at 220A resolution. Structure (1995) 3:503–513.
   PubMed Web of Science ®Google Scholar
• BRETON R, HOUSSET D, MAZZA C, FONTECILLA-CAMPS JC: The structure of a complex of human 17 P-hydroxy-steroid dehydrogenase with estradiol and NADP± identifies two principal targets for design of inhibi-tors. Structure (1996) 4:905–915.
   PubMed Web of Science ®Google Scholar
• MAZZA C, BRETON R, HOUSSET D, FONTECILLA-CAMPS JC: Unusual charge stabilisation of NADP+in 173-hydroxysteroid dehydrogenase. J. Biol. Chem. (1998) 273:8145–8152.
   PubMed Web of Science ®Google Scholar
• HAN Q, CAMPBELL RL, GANGLOFF A et al.: Dehydroepi-androsterone and dihydrotestosterone recognition by human estrogenic 173-hydroxysteroid dehydroge-nase- C-18/C-19 steroid discrimination and enzyme-induced strain. J Biol. Chem. (2000) 275:1105–1111.
   PubMed Web of Science ®Google Scholar
• ZHU DW, CAMPBELL R, LABRIE F et al: Crystallisation and preliminary crystal structure of the complex 173-hydroxysteroid dehydrogenase with a dual-site inhibitor. J. Steroid Biochem. Mol. Biol. (1999) 70:229–235.
   PubMedGoogle Scholar
• ••Future drug development/design.
   Google Scholar
• BORING CC, SQUIRES TS, TONG T: Cancer statistics, 1993. Cancer". Clin. (1993) 43:7–26.
   PubMed Web of Science ®Google Scholar
• GARCIASCHURMANN M, COFFEY DS: The concept of evolution in the pathogenesis and treatment of prostate cancer. Br. J. Urol. (1997) 79 (52):9–17.
   PubMedGoogle Scholar
• BYAR DP, MOSTOFI FK: Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer (1972) 30:5–13.
   Google Scholar
• SCARDINO PT, WEAVER R, HUDSON MA: Early detection of prostate cancer: classic aspects of prostate cancer pathology. Human Pathol. (1992) 23:211–222.
   PubMedGoogle Scholar
• OESTERLING JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. (1991) 145:907–923.
   PubMed Web of Science ®Google Scholar
• RUSSELL DW, WILSON JD: Steroid 5-alpha-reductase -2 genes 2 enzymes. Ann. Rev. Biochem. (1994) 63:25–61.
   PubMed Web of Science ®Google Scholar
• KIRSCHENBAUM A: Management of hormonal treatment effects. Cancer (1995) 75:1983–1986.
   Web of Science ®Google Scholar
• PILEPICH MV, KRALL JM, ALSARRAF Metal: Androgen deprivation with radiation-therapy compared with radiation-therapy alone for locally advanced prostatic-carcinoma - a randomized comparative trial of the radiation-therapy oncology group. Urology (1995) 45:616–623.
   PubMed Web of Science ®Google Scholar
• SMITH JA, JR.: New methods of endocrine management of prostatic cancer. J Urol. (1987) 137:1–10.
   PubMedGoogle Scholar
• CHO N, HARADA M, IMAEDA T et al.: Discovery of a novel, p otent and orally-active non-peptide antagonist of the human luteinizing hormone - releasing hormone (LIIRI-1) receptor. J. Merl. Chem. (1998) 41:4190–4195.
   PubMed Web of Science ®Google Scholar
• DE VITTA RJ, HOLLINGS DD, GOULET MT et al.: Identifi-cation and initial structure-activity relationships of a novel non-peptide quinolone GnRH receptor antago-nist. Bioorg. Merl. Chem. Lett. (1999) 9:2615–2620.
   PubMedGoogle Scholar
• DE VITTA RJ, GOULET MT, WYVRATT MJ et al.: Investiga-tion of the 4-0-alkylamine substituent of non-peptide quinolone GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (1999) 9:2621–2624.
   PubMedGoogle Scholar
• WALSH TF, TOUPENCE RB, YOUNG JR et al.: Potent antagonists of gonadotropin releasing hormone receptors derived from quinolone-6-carboxamides. Bioorg. Merl. Chem. Lett. (2000) 10:443–447.
   PubMed Web of Science ®Google Scholar
• BRUCHOVSKY N, WILSON JD: The conversion of testos-terone to 5a-androstan-1713-o1-3-one by rat prostate in ViVO and in vitro. J. Biol. Chem. (1968) 243:2012–2021.
   PubMed Web of Science ®Google Scholar
• MCCLELLAN KJ, MARKHAM A: Mnasteride - a review of its use in male pattern hair loss. Drugs (1999) 57:111–126.)
   PubMed Web of Science ®Google Scholar
• ••Good review.
   Google Scholar
• MARIKAR Y, WANG ZQ, DUELL EA, PETKOVICH M, VOORHEES JJ, FISHER GJ: Retinoic acid receptors regulate expression of retinoic acid 4-hydroxylase that specifically inactivates all-trans retinoic acid in human keratinocyte HaCaT cells. J. Invest. Dermatol (1998) 111:434–439.
   PubMed Web of Science ®Google Scholar
• CATHER JC, LANE D, HEAPHY MR, NELSON BR: Mnaste-ride -An update and review. Cutts (1999) 64:167–172.
   PubMedGoogle Scholar
• ORNSTEIN DK, RAO GS, JOHNSON B, CHARLTON ET, ANDRIOLE GL: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology (1996) 48:901–905.
   PubMed Web of Science ®Google Scholar
• FLESHNER NE, TRACHENBERG J: Combination finaste-ride and flutamide in advanced carcinoma of the prostate - effective therapy with minimal side-effects. Urol. (1995) 154:1642–1645.
   Google Scholar
• KENNY B, BALLARD S, BLAGG J et al.: Pharmacological options in the treatment of benign prostatic hyperplasia. J Merl. Chem. (1997) 40:1293–1315.
   PubMed Web of Science ®Google Scholar
• ABELL AD, HENDERSON BR: Steroidal and nonsteroidal inhibitors of 5-alpha-reductase. Curr. Med. Chem. (1995) 2:583–597.
   Web of Science ®Google Scholar
• ••Good review.
   Google Scholar
• FRYE SV: Inhibitors of 5-alpha-reductase. Curr. Pharm. Des. (1996) 2:59–84.
   Google Scholar
• ••Good review.
   Google Scholar
• JARMAN M, SMITH HJ, NICHOLLS PJ, SIMONS C: Inhibi-tors of enzymes of androgen biosynthesis: cytochrome P45017a and 5a-steroid reductase. Nat. Prod. Rep. (1998) 15:495–512.
   PubMedGoogle Scholar
• ••Good review.
   Google Scholar
• IEHLE C, DELOS S, GUIROU 0 et al.: Human prostatic steroid 5-alpha-reductase isoforms - a comparative-study of selective inhibitors. J. Steroid Biochem. Mol Biol. (1995) 54:273–299.
   Google Scholar
• BULL MG: Mechanism-based inhibition of human steroid 5 alpha-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, potent bisubstrate analog inhibitor. J Am. Chem. Soc. (1996) 118:2359–2365.
   Web of Science ®Google Scholar
• MOSS ML, KUZMIC JP, STUART G et al.: Inhibition of human steroid 5 alpha reductase Type I and II by 6-aza-steroids: structural determinants of one-step VS. two-step mechanism. Biochemistry (1996) 35:3457-3464. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(5)
   Google Scholar
• ELLSWORTH KP, AZZOLINA BA, CIMIS G et al.: Cloning, expression and characterisation of rhesus macaque types 1 and 2 5a-reductase: evidence for mechanism-based inhibition by finasteride. J. Steroid Biochem. Mol. Biol. (1998) 66:271–279.
   PubMed Web of Science ®Google Scholar
• MCCONNELL JD: Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol. N Am. (1990) 17:661–670.
   PubMed Web of Science ®Google Scholar
• DI SALLE E, GIUDICI D, BRIATICO G, ORNATI G, PANZERI A: Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J. Steroid Biochem. Mol Biol. (1993) 46:549–555.
   PubMedGoogle Scholar
• DI SALLE E, BRIATICO G, GIUDICI D, ORNATI G, PANZERI A: Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073). J Steroid Biochem. Mol Biol. (1994) 48:241–248.
   PubMed Web of Science ®Google Scholar
• ZACCHEO T, GIUDICI D, DISALLE E: Effects of turoste-ride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate (1997) 30:85–91.
   PubMed Web of Science ®Google Scholar
• NORMINGTON K, RUSSELL DW: Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. J. Biol. Chem. (1992) 267:19548–19554.
   PubMed Web of Science ®Google Scholar
• STONER E: The effect of finasteride in men with benign prostatic hyperplasia. j Urol. (1992) 147:1298–1302.
   PubMed Web of Science ®Google Scholar
• MOCELLINI Al, GARDINER R, MARSHALL V et al.: Hnaste-ride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate (1993) 22:291–299.
   PubMedGoogle Scholar
• STONER E: Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch. Intern. Med. (1994) 154:83–88.
   PubMed Web of Science ®Google Scholar
• BAKSHI RK, RASMUSSON GH, PATEL GF et al: 4-aza-3-oxo-5-alpha-androst-1-ene-17-beta-N-aryl-carbox-amides as dual inhibitors of human type-1 and type-2 steroid 5-alpha-reductase - dramatic effect of N-aryl substituents on type-1 and type-2 5-alpha reductase inhibitory potency. J Med. Chem. (1995) 38:3189–3192.
   PubMedGoogle Scholar
• TIAN GC, MOOK RA, MOSS ML et al.: Mechanism of time-dependent inhibition of 5-alpha-reductase by delta(1)-4-azasteroids - towards perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry (1995) 43:13453–13459.
   Google Scholar
• GIUDICI D, BRIATICO G, COMINATO C et al.: FCE28260, a new alpha-reductase inhibitor: In vitro and in vivo effects. J. Steroid Biochem. Mol. Biol. (1996) 58:299–305.
   PubMed Web of Science ®Google Scholar
• ELLSWORTH K, AZZOLINA B, BAGINSKY W et al: MK386: a potent, selective inhibitor of the human Type 1 5-alpha reductase. J. Steroid Biochem. Mol. Biol. (1996) 58:377–384.
   PubMedGoogle Scholar
• FRYE SV, HAFFNER CD, MALONEY PR et al.: Structure-activity-relationships for inhibition of type-1 and type-2 human 5-alpha-reductase and human adrenal 3-beta-hydroxy-delta(5)-steroid dehydrogenase 3-keto-delta(5)-steroid isomerase by 6-azaandrost-4-en-3-ones -optimization of the C17 substituent. J. Med. Chem. (1995) 38:2621–2627.
   PubMed Web of Science ®Google Scholar
• LEVY MA, BRANDT M, SHEEDY KM et al: Episteride is a selective and specific uncompetitive inhibitor of human steroid 5-alpha-reductase isoform-2 J Steroid Biochem. Mol. Biol. (1996) 48:197–206.
   Google Scholar
• SUN ZY, WUHY, WANG MY et al: The mechanism of episteride against benign prostatic hyperplasia. Eur. Pharmacol. (1999) 371 :227–233.
   PubMedGoogle Scholar
• YAMASHITA DS, HOLT DA OH HJ et al: 3-Carboxy-20-keto steroids are dual uncompetitive inhibitors of human steroid 5 alpha-reductase types 1 and 2 Bioorg. Med. Chem. (1996) 4:1481–1485.
   Google Scholar
• NORMINGTON K, RUSSELL DW: Tissue distribution and kinetic characteristics of rat steroid 5-alpha-reductase isozymes - evidence for distinct physiological functions. J Biol. Chem. (1992) 267:19548–19554.
   PubMed Web of Science ®Google Scholar
• BLAGG J, BALLARD SA, COOPER K et al: The develop-ment of non-steroidal dual inhibitors of both human 5 alpha-reductase isozymes. Bioorg. Med. Chem. Lett. (1996) 6:1517–1522.
   Google Scholar
• SMITH CM, BALLARD SA, WORMAN N et al.: 5-Alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J. Clin. Endocrinol. Metab. (1996) 81:1361–1366.
   PubMed Web of Science ®Google Scholar
• KOJO H, NAKAYAMA 0, HIROSUMI J et al.: Novel steroid 5-alpha-reductase inhibitor FK143 -its dual inhibition against the 2-isoforms and its effect on transcription of the isozyme genes. Mol. Pharmacol. (1995) 48:401–406.
   Google Scholar
• HIROSUMI J, NAKAYAMA 0, CHIDA N et al: FK143, a novel nonsteroidal inhibitor of steroid 5-alpha-reductase. 2. hi-vivo effects on rat and dog prostates. J Steroid Biochem. Mol. Biol. (1995) 52:365–373.
   Google Scholar
• HOMMA Y, KANEKO M, KONDO Y etal.: Inhibition of rat prostate carcinogenesis by a 5 alpha-reductase inhibitor, FK143 J. Natl. Cancer Inst. (1997) 89:803–807.
   Google Scholar
• KATASHIMA M, IRINO T, SHIMOJO F et al: Pharmacoki-netics and pharmacodynamics of FK143, a nonster-oidal inhibitor of steroid 5a-reductase, in healthy volunteers. Clin. Pharmacol Ther. (1998) 63:354–366.
   PubMedGoogle Scholar
• KATASHIMA M, YAMAMOTO K, TOKUMA Y et al.: Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5a-reductase inhibitor 4-[3-[3-Ibis (4-isobutylphenyl)methylamino]benzoy1]-1H-indol-1 -yli-butyric acid in rats. J. Pharmacol. Exp. Ther. (1998) 284 :914–920.
   PubMedGoogle Scholar
• KATASHIMA M, YAMAMOTO K, HARAGUCHI K et al.: Tissue distribution kinetics of a new nonsteroidal 5a-reductase inhibitor, 4[3434bis(4-isobutylphenyl) methylamino]benzoy1]-1H-indo1-1-yl] butyric acid. Drug Metab. Disp. (1997) 25:1051–1058.
   PubMedGoogle Scholar
• INAMI M, KAWAMURA I, NAOE Y et al.: Effects of a new non-steroidal 5a-reductase inhibitor, FK143, on the prostate gland in beagle dogs. Jpn. J. Pharmacol. (1997) 2:187–194.
   Google Scholar
• NAKAYAMA 0, HIROSUMI J, CHIDA N et al: FR146687, a novel steroid 5 alpha-reductase inhibitor: In vitro and in vivo effects on prostates. Prostate (1997) 31:241–249.
   PubMedGoogle Scholar
• HOLT DA, YAMASHITA DS, KONIALIAN-BECK AL et al: Benzophenonecarboxylic and indolecarboxylic acids - potent type-2 specific inhibitors of human steroid 5-alpha-reductase. J Med. Chem. (1995) 38:13–15.
   PubMedGoogle Scholar
• WILDE MI, GOA KL: Finasteride -An update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs (1999) 57:557–581.
   PubMed Web of Science ®Google Scholar
• HUDSON PB, BOAKE R, TRACHTENBERG J, ROMAS NA, ROSENBLATT S, NARAYAN P: Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. Urology (1999) 53:690–695.)
   PubMed Web of Science ®Google Scholar
• MARBERGER MJ: Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. Urology (1998) 51:677–686.
   PubMed Web of Science ®Google Scholar
• PRESTI JC, JR., FAIR WR, ANDRIOLE G et al: Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol. (1992) 148:1201–1204.
   PubMedGoogle Scholar
• ANDRIOLE GL, CATALONA WJ: Prostate carcinoma. Ann. Rev. Med. (1994) 45:351–359.
   PubMedGoogle Scholar
• FEIGL P, BLUMENSTEIN B, THOMPSON I et al.: Design of the Prostatic Cancer Prevention Trial (PCPT). Control. Clin. Trials (1995) 16:150–163.
   PubMedGoogle Scholar
• LUNN RM, BELL DA, MOHLER JL et al.: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (1999) 20: 1727-1731.
   Google Scholar
• •Reports important findings.
   Google Scholar
• FEBBO PG, KANTOFF PW, PLATZ EA et al.: The V89L polymorphism in the 5a-reductase Type 2 gene and risk of prostate cancer. CancerRes. (1999) 59:5878–5881.
   Google Scholar
• •Reports important findings.
   Google Scholar
• AKULU A, ELMAJIAN DA, HIGHSHAW RA et al.: Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5a-reductase during prostate cancer progres-sion. J. Urology (1999) 161:1355–1358.
   PubMedGoogle Scholar
• VANDEN BOSSCHE H, MOEREELS H: 17a-Hydroxylase/ 17,20-lyase. In: Design of Enzyme Inhibitors as Drugs. Sandler M, Smith HJ (Eds.), Oxford University Press, Oxford (1994) 2:438–461.
   Google Scholar
• BARRIE SE, JARMAN M: Inhibitors of cytochrome P450 (17 alpha) (17 alpha-hydroxylase/C-17,20 lyase). Endocr. Rel. Cancer (1996) 3:25–39.
   Google Scholar
• ••Good review.
   Google Scholar
• NJAR VCO, BRODIE AMH: Inhibitors of 17a-hydrox-ylase/17,20-lyase (CYP 17): Potential agents for the treatment of prostate cancer. CUIT. Pharm. Design (1999) 5:163–180.
   PubMedGoogle Scholar
• ••Good review.
   Google Scholar
• TRACHTENBERG J, ZADRA J: Steroid synthesis inhibi-tion by ketoconazole: sites of action. Clin. Invest. Med. (1988) 11:1–5.
   PubMedGoogle Scholar
• MASON JI, CARR BR, MURRAY BA: Irnidazole antimy-cotics: selective inhibitors of steroid aromatization and progesterone hydroxylation. Steroids (1987) 50:179–189.
   PubMedGoogle Scholar
• AYUB M, LEVELL MJ: Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxy-steroid dehydrogenase-isomerase or 17 beta- hydrox-ysteroid oxidoreductase by ketoconazole and other imidazole drugs. J. Steroid Biochem. (1987) 28:521–531.
   PubMedGoogle Scholar
• VANDEN BOSSCHE H, WILLEMSENS G, BELLENS D, ROELS I, JANSSEN PAJ: From 14a-demethylase inhibitors in fungal cells to androgen and oestrogen biosynthesis inhibitors in mammalian cells. Biochem. Soc. Trans. (1990) 18:10–13.
   PubMedGoogle Scholar
• BRUYNSEELS J, DECOSTER R, VAN ROOY P et al.: R75251, a new inhibitor of steroid synthesis. Prostate (1990) 16:345–347.
   Google Scholar
• VANDEN BOSSCHE H, WILLEMSENS G: Retinoic acid and cytochrome P-450 In: Retinoic acid:10 Years On. Saurat J-H (Ed.), Karger, Basel, Switzerland (1990:79–88.
   Google Scholar
• ••Good review.
   Google Scholar
• DE COSTER R, WOUTERS W, VAN GINKEL R et al.: Experi-mental studies with liarozole (R75251): an anti-tumoral agent which inhibits retinoic acid breakdown. J. Steroid Biochem. MM. Biol. (1992) 43:197–201.
   Google Scholar
• VAN WAUVVE J, VAN NYEN G, COENE M-J et al.: liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J. Pharmacol. Exp. Ther. (1992) 261:773–779.
   PubMedGoogle Scholar
• MILLER WH: The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer (1998) 83:1471–1482.
   PubMed Web of Science ®Google Scholar
• ••Good review.
   Google Scholar
• FREYNE E, RAEYMAEKERS A, VENET M et al: Synthesis of Liazal (TM), a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology. Bioorg. Med. Chem. Lett. (1998) 8:267–272.
   PubMedGoogle Scholar
• RANER GM, VAZ AD, COON MJ: Metabolism of all-trans, 9-cisand13-cisisomers of retinal by purified isozymes of microsomal cytochrome P-450 and mechanism-based inhibition of retinoid oxidation by citral. Mol Pharmacol. (1996) 49:515–522.
   PubMed Web of Science ®Google Scholar
• ROBERTS AB, LAMB LC, SPORN MB: Metabolism of all-trans-retinoic acid in hamster liver microsomes: oxidation of 4-hydroxy- to 4-keto-retinoic acid. Arch. Biochem. Biophys. (1980) 199:374–383.
   PubMed Web of Science ®Google Scholar
• VAN WAUVVE J, COENE M-C, COOLS W et al.: liarozole fumarate inhibits the metabolism of 4-keto-all-trans retinoic acid. Biochem. Pharmacol. (1994) 47:737–741.
   PubMedGoogle Scholar
• VAN WAUVVE JP, COENE M-C, GOOSSENS J, COOLS W, MONBALIU J: Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J. Pharmacol. Exp. Ther. (1990) 252:365–369.
   PubMedGoogle Scholar
• GOSS PE, OZA A, GOEL R, NABHOLTZ JM, DECOSTER R, BRUYNSEELS J et al.: liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer. Breast Cancer Res. Treat. (2000) 59:55–68.
   PubMedGoogle Scholar
• OBYRNE KJ, HAN C, MITCHELL K et al.: Phase II study of liarozole in advanced non-small cell lung cancer. Eur. J. Cancer (1998) 34:1463–1466.
   PubMedGoogle Scholar
• DENIS L, DEBRUYNE F, DEPORRE P, BRUYNSEELS J: Early clinical experience with Liarozole (Liaza17) in patients with progressive prostate cancer. Eur. J. Cancer (1998) 34:469–475.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE FJM, MURRAY R, FRADET Y et al: liarozole - A novel treatment approach for advanced prostate cancer: results of a large randomised trial versus cyproterone acetate. Urology (1998) 52:72–81.
   PubMedGoogle Scholar
• KUIJPERS ALA, VANPELT JPA, BERGERS M et al.: The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br. J Dermatol. (1998) 139:380–389.
   PubMedGoogle Scholar
• LY RH, ZHAO XY, HOLLOWAY L, FELDMAN D: liarozole acts synergistically with 1 alpha, 25-dihy dr o x yvitamin D-3 to inhibit growth of DU145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocri-nology (1999) 140:2071–2076.
   PubMedGoogle Scholar
• •A major advance in the field.
   Google Scholar
• AHMAD M, NICHOLLS PJ, SMITH HJ, AHMADI M: Effect of P450 isozyme-selective inhibitors on in-vitro metabo-lism of retinoic acid by rat hepatic microsomes. Pharm. Pharmacol (2000) 52:311–314.
   PubMedGoogle Scholar
• STOPPIE P, BORGERS M, BORGHGRAEF P et al.: R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoid effects in rodents. J. Pharmacol Exp. Ther. (2000) 293:304–312.
   PubMed Web of Science ®Google Scholar
• ••New target for retinoic acid metabolism.
   Google Scholar
• AL-HAMROUNI AA, AHMADI M, NICHOLLS PJ, SMITH HJ, LOMBARDI P, PESTELLINI V:1-[(Ben zo furan-2-y1)-phenylmethyl] imidazoles as inhibitors of 17a-hydroxylase:17,20-lyase (P450 17): species and tissue differences. Pharm. ScL (1997) 3:259–263.
   Google Scholar
• BASHWAN SA, OWEN CP, NICHOLLS PJ, SMITH HJ, AHMADI M: Some 1 -[(benzo fur an -2-yl)methy1]-imidazoles as inhibitors of 17a-hydroxylase; 17-20-lyase (P450 17) and their specificity patterns. j Pharm. Pharmacol. (1998) 50:1109–1116.
   PubMedGoogle Scholar
• WACHALL BG, HECTOR M, ZHUANG Y et al.: Irnidazole substituted diphenyls: anew class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for the treatment of prostate cancer. Bioorg. Med. Chem. (1999) 7:1913–1924.
   PubMed Web of Science ®Google Scholar
• IDEYAMA Y, KUDOH M, TANIMOTO K et al.: Novel non-steroidal inhibitors of cytochrome P450 (17a) (17a-hydroxylase/C17-20 lyase), YM 116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats. Prostate (1998) 37:10–18.
   PubMed Web of Science ®Google Scholar
• SERGEJEW T, HARTMANN RW: Pyridyl substituted benzocycloalkenes - new inhibitors of 17-alpha-hydroxylase-17,20-lyase (P450 17-alpha) J Enzym. Inhib. (1994) 8:113–122.
   PubMed Web of Science ®Google Scholar
• MCCAGUE R, ROWLANDS MG, BARRIE S et al: Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid. J Med. Chem. (1990) 33:3050–3055.
   PubMed Web of Science ®Google Scholar
• ROWLANDS MG, BARRIE SE, CHAN F, HOUGHTON J, JARMAN M, MCCAGUE R: Esters of 3-pyridylacetic acid that combine potent inhibition of 17-alpha-hydroxylase C-17,C-20-lyase (cytochrome P450-alpha)with resistance to esterase hydrolysis. J Med. Chem. (1995) 38:4191–4197.
   PubMed Web of Science ®Google Scholar
• BARRIE SE, HAYNES BP, POTTER GA et al.: Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450 (17 alpha) inhibitors. J Steroid Biochem. Mol. Biol. (1997) 60:347–351.
   PubMedGoogle Scholar
• CHAN FCY, POTTER GA, BARRIE SE et al.: 3- and 4-pyridylalkyl-adamantanecarboxylates: inhibitors of human cytochrome P450 (17 alpha) (17 alpha-hydroxylase/C-17,C-20-lyase): Potential nonsteroidal agents for the treatment of prostatic cancer. j Med. Chem. (1996) 39:3319–3323.
   PubMedGoogle Scholar
• BARRIE SE, HAYNES BP, POTTER GA, CHAN FCX, GODDARD PM, DOWSETT M: Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450 (17 alpha) inhibitors. J Steroid Biochem. Mol. Biol. (1997) 60:347–351.
   PubMedGoogle Scholar
• ARTH GE, PATCHETT AA, JEFOPOULUS T et al.: Steroidal androgen biosynthesis inhibitors. J Med. Chem. (1971) 14:675–679.
   PubMedGoogle Scholar
• NJAR VCO, HECTOR M, HARTMANN RW: 20-Amino and 20,21-aziridinyl pregnene steroids: development of potent inhibitors of 17 alpha-hydroxylase C17,C20-lyase (P450 17). Bioorg. Med. Chem. (1996) 4:1447–1453.
   PubMedGoogle Scholar
• POTTER GA, BARRIE SE, AKHTAR M et al: The impact of aromatase mechanism on other P450s. J. Steroid Biochem. Mol. Biol. (1997) 61:127–132.
   PubMedGoogle Scholar
• BARRIE SE, POTTER GA, GODDARD PM, HAYNES BP, DOWSETT M, JARMAN M: Pharmacology of novel steroidal inhibitors of cytochrome P450 (17-alpha) (17-alpha-hydroxylase C17-20 lyase). J. Steroid Biochem. Mol. Biol. (1994) 50:267–273.
   PubMed Web of Science ®Google Scholar
• •A major advance in the field.
   Google Scholar
• JARMAN M, BARRIE SE, LLERA JM: The 16,17-double bond is needed for irreversible inhibition of human cytochrome P450 (17 alpha) by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3-beta-ol) and related steroidal inhibitors. J. Med. Chem. (1998) 41:5375–5381.
   PubMed Web of Science ®Google Scholar
• NJAR VCO, KATO K, NNANE IP, GRIGORYEV DN, LONG BJ, BRODIE AMH: Novel 17-azoyl steroids, potent inhibitors of human cytochrome 17-alpha-hydroxylase-C-17, C-20-lyase (P450 (17 alpha)): potential agents for the treatment of prostate cancer. J Med. Chem. (1998) 41:902–912.
   PubMedGoogle Scholar
• ANGELASTRO MR, LAUGHLIN ME, SCHATZMAN GL et al.:17-Beta-(cyclopropylamino)-androst-5-en-3-beta- ol, a selective mechanism-based inhibitor of cytochrome P450 17-alpha (steroid 17-alpha hydroxylase-C-17,C-20 lyase). Biochem. Biophys. Res. Commun. (1989) 162:1571–1577.
   PubMed Web of Science ®Google Scholar